Francine Figg
Nurse Practitioner · Indianapolis, INNPI 1629511365
Payments from drug & device makers
Across 55 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$176
- Incyte Corporation$159
- Pharmacyclics LLC, An Abbvie Company$120
- AbbVie$108
- Genmab U.S., Inc.$103
- Johnson & Johnson$90
- plus $568 from 19 others
What the payments were for
- Food & beverage$1,11284%
- Education$21116%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $176 |
| Incyte Corporation | 4 | $159 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $120 |
| AbbVie | 5 | $108 |
| Genmab U.S., Inc. | 6 | $103 |
| Johnson & Johnson | 3 | $90 |
| Tempus AI, Inc | 3 | $60 |
| Acrotech Biopharma Inc. | 2 | $51 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Sanofi | 2 | $42 |
| GSK | 2 | $37 |
| ADC Therapeutics America, Inc. | 2 | $36 |
| Amgen | 2 | $35 |
| Sanofi-aventis U.S. LLC | 1 | $33 |
| Bristol Myers Squibb | 2 | $30 |
| AstraZeneca | 1 | $29 |
| Beigene USA, Inc. | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Biolinerx USA, Inc. | 1 | $22 |
| Legend Biotech USA Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Morphosys, US Inc. | 1 | $14 |
| Rigel Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,324 in reported general payments places this provider in the 75th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $12,769 |
| Acyclovir | 70 | $1,911 |
| Fluconazole | 14 | $398 |
| Potassium Chloride | 17 | $201 |
| Gabapentin | 17 | $192 |
| Ondansetron OdtOndansetron | 14 | $184 |
| Klor-Con M20Potassium Chloride | 12 | $151 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 36 | $147 |
| Tamsulosin Hcl | 14 | $90 |
| Azithromycin | 12 | $85 |
| Prednisone | 18 | $81 |
| Montelukast Sodium | 18 | $77 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Indianapolis
- Kristi OrbaughIndianapolis$1.3M
- Kacy RogersIndianapolis$77K
- Brittany SavageIndianapolis$51K
- Jennifer MaahsIndianapolis$36K
- Dawn SteppIndianapolis$31K
- Allison FrayerIndianapolis$26K
- Angela PierceIndianapolis$19K
- Donna DoerfflerIndianapolis$13K
- Shannon ColterIndianapolis$12K
- Ellen RovnerIndianapolis$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.